title: A novel Bcr-Abl splice isoform is associated with the L248V mutation in CML patients with acquired resistance to imatinib.
authors.forename: F X
authors.initials: FX
authors.lastname: Gruber
authors.forename: H
authors.initials: H
authors.lastname: Hjorth-Hansen
authors.forename: I
authors.initials: I
authors.lastname: Mikkola
authors.forename: L
authors.initials: L
authors.lastname: Stenke
authors.forename: T
authors.initials: T
authors.lastname: Johansen
mesh_terms: D000368:Aged; D017398:Alternative Splicing; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D019008:Drug Resistance, Neoplasm / Q000235:genetics; D016044:Fusion Proteins, bcr-abl / Q000235:genetics*; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000235:genetics*; D008297:Male; D010879:Piperazines / Q000627:therapeutic use*; D017354:Point Mutation; D011743:Pyrimidines / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D016044:Fusion Proteins, bcr-abl